GlassScriptPhysician profile
Vicki L Steen
NPI 1982638201
$3,545.49
in general payments reported to CMS, 2019-2025
33 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $481 · 2021: $896 · 2022: $736 · 2023: $589 · 2024: $239 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.99 |
| Education | $111.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $906.10 | 2019-2023 | Liletta |
| Astellas Pharma US INC | $455.39 | 2022-2025 | Veozah |
| Avion Pharmaceuticals | $397.47 | 2019-2023 | Balcoltra, NP Thyroid 60 |
| Mayne Pharma Commercial LLC | $342.45 | 2021-2025 | |
| Therapeuticsmd, INC. | $237.52 | 2019-2022 | |
| Millicent US INC | $141.53 | 2019-2025 | Femring, Intrarosa |
| Organon LLC | $120.25 | 2021-2023 | Nexplanon |
| Aspira Women'S Health INC | $85.39 | 2021 | |
| Applied Medical Resources Corporation | $82.16 | 2022 | |
| Scynexis, INC. | $78.79 | 2022 | |
| Pfizer INC. | $75.32 | 2019-2023 | |
| Mylan Pharmaceuticals INC. | $68.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $47.38 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.61 | 2020-2023 | |
| Novo Nordisk INC | $44.63 | 2022-2023 | Wegovy, Saxenda |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.75 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $36.98 | 2019 | |
| Revance Therapeutics, INC. | $34.80 | 2024 | Daxxify |
| Exeltis, USA INC. | $32.32 | 2019-2020 | |
| Agile Therapeutics, INC. | $32.07 | 2021 | |
| Sumitomo Pharma America, INC. | $31.92 | 2024-2025 | Myfembree, Gemtesa |
| Dexcom, INC. | $24.37 | 2025 | Dexcom G6 Transmitter |
| Duchesnay USA Incorporated | $24.01 | 2019 | |
| Allergan, INC. | $23.96 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $19.27 | 2021 | |
| Mission Pharmacal Company | $17.74 | 2019 | |
| Currax Pharmaceuticals LLC | $17.30 | 2023 | Contrave |
| Evofem Biosciences, INC. | $15.27 | 2021 | |
| Lupin INC. | $13.78 | 2020 | |
| Lsi Solutions INC | $13.10 | 2021 | |
| Meditrina | $12.91 | 2025 | |
| Myovant Sciences INC. | $12.74 | 2021 | |
| Becton, Dickinson and Company | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Steen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.